Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D02YPU
|
|||
| Former ID |
DNCL002966
|
|||
| Drug Name |
Pyridoxamine
|
|||
| Synonyms |
Pyridorin (TN)
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Diabetic kidney disease [ICD-11: GB61.Z] | Phase 3 | [1] | |
| Diabetic nephropathy [ICD-11: GB61.Z] | Phase 3 | [1] | ||
| Company |
Nephrogenex
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C8H12N2O2
|
|||
| Canonical SMILES |
CC1=NC=C(C(=C1O)CN)CO
|
|||
| InChI |
1S/C8H12N2O2/c1-5-8(12)7(2-9)6(4-11)3-10-5/h3,11-12H,2,4,9H2,1H3
|
|||
| InChIKey |
NHZMQXZHNVQTQA-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 85-87-0
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
3816, 831723, 835061, 835065, 835069, 4252720, 4451228, 7890124, 8143574, 8150947, 10319847, 10537035, 11142447, 11406185, 11457881, 11459944, 15194988, 24305802, 24439405, 26651867, 29196271, 29196274, 47217156, 49737755, 50070585, 50071196, 50108077, 50397717, 53776771, 57320699, 57566563, 57641282, 85089056, 85164961, 91056273, 92298009, 103717483, 104296624, 104813139, 118299127, 124635911, 124877191, 125616993, 126524049, 126671835, 127280580, 127280581, 127280582, 127280583, 127329709
|
|||
| ChEBI ID |
CHEBI:16410
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Advanced glycosylation end product receptor (AGER) | Target Info | Inhibitor | [2], [3] |
| Pathway Interaction Database | amb2 Integrin signaling | |||
| Reactome | RIP-mediated NFkB activation via ZBP1 | |||
| DEx/H-box helicases activate type I IFN and inflammatory cytokines production | ||||
| TAK1 activates NFkB by phosphorylation and activation of IKKs complex | ||||
| Advanced glycosylation endproduct receptor signaling | ||||
| TRAF6 mediated NF-kB activation | ||||
| WikiPathways | NRF2 pathway | |||
| Nuclear Receptors Meta-Pathway | ||||
| Cytosolic sensors of pathogen-associated DNA | ||||
| TAK1 activates NFkB by phosphorylation and activation of IKKs complex | ||||
| AGE/RAGE pathway | ||||
| RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways | ||||
| Advanced glycosylation endproduct receptor signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02156843) Pyridorin in Diabetic Nephropathy. U.S. National Institutes of Health. | |||
| REF 2 | Pyridoxamine, an inhibitor of advanced glycation end product (AGE) formation ameliorates insulin resistance in obese, type 2 diabetic mice. Protein Pept Lett. 2010 Sep;17(9):1177-81. | |||
| REF 3 | The AGE inhibitor pyridoxamine inhibits development of retinopathy in experimental diabetes. Diabetes. 2002 Sep;51(9):2826-32. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.